FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568029230> ?p ?o ?g. }

• W2568029230 endingPage "587" @default.
• W2568029230 startingPage "581" @default.
• W2568029230 abstract "Hepatitis B core antibody (HBcAb) seropositivity has been associated with a higher rate of hepatitis B virus (HBV) reactivation after chemotherapy, even in patients who are hepatitis B surface antigen (HBsAg) negative. However, little is known about the risk of HBV reactivation after autologous hematopoietic stem cell transplantation (auto-HCT). We evaluated the incidence of HBV reactivation, liver toxicity, and survival in patients with multiple myeloma (MM) who received auto-HCT at our institution. We retrospectively identified 107 MM patients with resolved HBV infection (HBcAb positive, HBsAg negative) and 125 patients with negative HBV serology (control subjects) who were matched for age, timing of auto-HCT from diagnosis, cytogenetics, disease status at transplant, induction therapy, and preparative regimen. All patients underwent auto-HCT between 1991 and 2013. Primary endpoints were HBV reactivation, defined as HBsAg positivity or ≥10-fold increase in HBV DNA, and hepatotoxicity, as defined in the U.S. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. In the resolved HBV infection group, 52 patients (49%) were HBsAb positive and 24 (22%) had detectable HBV DNA before auto-HCT. Only 1 patient with resolved HBV infection received pre-emptive antiviral therapy with lamivudine, whereas 4 patients received lamivudine (n = 3) or tenofovir (n = 1) at reactivation after auto-HCT for a median duration of 12 months. HBV reactivation occurred in 7 of 107 patients (6.5%) in the resolved HBV group. Median time to HBV reactivation from auto-HCT was 16 months. The cumulative incidence of grade 2 or greater hepatotoxicity was 30% in the resolved HBV infection group and 22% in the control group (hazard ratio, 1.3; 95% confidence interval, .7 to 2.3; P = .4). Nonrelapse mortality for the 2 groups was not statistically different at 2 years (P = .06), although it trended higher in the control group than in the resolved HBV infection group (8% versus 1%). The median progression-free survival (PFS) and overall survival (OS) durations in the resolved HBV infection and control groups were 21 versus 18 months (P = .5) and 53 versus 67 months (P = .2), respectively. Our data suggest that resolved HBV infection in patients undergoing auto-HCT for MM is associated with a low risk of HBV reactivation and hepatotoxicity; these complications were reversible and did not adversely affect the PFS or OS." @default.
• W2568029230 created "2017-01-13" @default.
• W2568029230 creator A5001940718 @default.
• W2568029230 creator A5006472428 @default.
• W2568029230 creator A5008366988 @default.
• W2568029230 creator A5013826719 @default.
• W2568029230 creator A5015342719 @default.
• W2568029230 creator A5033842027 @default.
• W2568029230 creator A5047522685 @default.
• W2568029230 creator A5048913229 @default.
• W2568029230 creator A5050962913 @default.
• W2568029230 creator A5053904944 @default.
• W2568029230 creator A5065998208 @default.
• W2568029230 creator A5066894053 @default.
• W2568029230 creator A5068834306 @default.
• W2568029230 creator A5076249582 @default.
• W2568029230 creator A5084307578 @default.
• W2568029230 date "2017-04-01" @default.
• W2568029230 modified "2023-10-18" @default.
• W2568029230 title "Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma" @default.
• W2568029230 cites W1813391014 @default.
• W2568029230 cites W1839481170 @default.
• W2568029230 cites W1867112730 @default.
• W2568029230 cites W1966771497 @default.
• W2568029230 cites W1967577450 @default.
• W2568029230 cites W1969294339 @default.
• W2568029230 cites W1972172571 @default.
• W2568029230 cites W1972321006 @default.
• W2568029230 cites W1979792611 @default.
• W2568029230 cites W1984724288 @default.
• W2568029230 cites W1994245137 @default.
• W2568029230 cites W1997047331 @default.
• W2568029230 cites W2000635340 @default.
• W2568029230 cites W2025722002 @default.
• W2568029230 cites W2025821693 @default.
• W2568029230 cites W2031317669 @default.
• W2568029230 cites W2033841261 @default.
• W2568029230 cites W2035068924 @default.
• W2568029230 cites W2038360824 @default.
• W2568029230 cites W2046386392 @default.
• W2568029230 cites W2061551385 @default.
• W2568029230 cites W2063204185 @default.
• W2568029230 cites W2065493998 @default.
• W2568029230 cites W2067109440 @default.
• W2568029230 cites W2083101441 @default.
• W2568029230 cites W2096895966 @default.
• W2568029230 cites W2101867956 @default.
• W2568029230 cites W2102591890 @default.
• W2568029230 cites W2105403730 @default.
• W2568029230 cites W2123697066 @default.
• W2568029230 cites W2136778441 @default.
• W2568029230 cites W2140505684 @default.
• W2568029230 cites W2145773930 @default.
• W2568029230 cites W2146343857 @default.
• W2568029230 cites W2147134417 @default.
• W2568029230 cites W2151648675 @default.
• W2568029230 cites W2161758234 @default.
• W2568029230 cites W2163485691 @default.
• W2568029230 cites W2164196535 @default.
• W2568029230 cites W2169366919 @default.
• W2568029230 cites W2460539353 @default.
• W2568029230 cites W4211026375 @default.
• W2568029230 cites W56605606 @default.
• W2568029230 doi "https://doi.org/10.1016/j.bbmt.2017.01.005" @default.
• W2568029230 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5749257" @default.
• W2568029230 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28063964" @default.
• W2568029230 hasPublicationYear "2017" @default.
• W2568029230 type Work @default.
• W2568029230 sameAs 2568029230 @default.
• W2568029230 citedByCount "14" @default.
• W2568029230 countsByYear W25680292302017 @default.
• W2568029230 countsByYear W25680292302019 @default.
• W2568029230 countsByYear W25680292302020 @default.
• W2568029230 countsByYear W25680292302021 @default.
• W2568029230 countsByYear W25680292302022 @default.
• W2568029230 crossrefType "journal-article" @default.
• W2568029230 hasAuthorship W2568029230A5001940718 @default.
• W2568029230 hasAuthorship W2568029230A5006472428 @default.
• W2568029230 hasAuthorship W2568029230A5008366988 @default.
• W2568029230 hasAuthorship W2568029230A5013826719 @default.
• W2568029230 hasAuthorship W2568029230A5015342719 @default.
• W2568029230 hasAuthorship W2568029230A5033842027 @default.
• W2568029230 hasAuthorship W2568029230A5047522685 @default.
• W2568029230 hasAuthorship W2568029230A5048913229 @default.
• W2568029230 hasAuthorship W2568029230A5050962913 @default.
• W2568029230 hasAuthorship W2568029230A5053904944 @default.
• W2568029230 hasAuthorship W2568029230A5065998208 @default.
• W2568029230 hasAuthorship W2568029230A5066894053 @default.
• W2568029230 hasAuthorship W2568029230A5068834306 @default.
• W2568029230 hasAuthorship W2568029230A5076249582 @default.
• W2568029230 hasAuthorship W2568029230A5084307578 @default.
• W2568029230 hasBestOaLocation W25680292301 @default.
• W2568029230 hasConcept C126322002 @default.
• W2568029230 hasConcept C203014093 @default.
• W2568029230 hasConcept C2522874641 @default.
• W2568029230 hasConcept C2777382497 @default.
• W2568029230 hasConcept C2777408962 @default.
• W2568029230 hasConcept C2777410769 @default.

• next